Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06872892 · ClinicalTrials.gov registry record · Phase 3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
A Phase 3 study of Bronchiectasis, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,755
- Enrollment target
- 20
- Study locations
NCT06872892: Recruiting Phase 3 study of Bronchiectasis, sponsored by Boehringer Ingelheim.
NCT06872892 is a Phase 3 study of Bronchiectasis that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 1,755 participants, above the 253-participant average among 13 other Bronchiectasis trials with a reported enrollment target (594% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06872892, a Phase 3 study of Bronchiectasis, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,755 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine. Participants take 1 tablet once a day for up to 1 year and 6 months. Participants are in the study for up to 1 year and 8 months. During this time, participants visit the study site up to 10 times and get about 13 phone calls from the site staff. Participants regularly complete a diary on a smartphone about their bronchiectasis symptoms and study doctors regularly check for any changes. The study doctors document when participants experience flare-ups. The number of flare-ups is compared between the participants who receive BI 1291583 and those who receive the placebo. The study doctors also regularly check participants' health and take note of any unwanted effects.
Conditions Studied
Interventions
- DRUG BI 1291583
- DRUG Placebo matching BI 1291583
Study Locations (20)
Florida
- Central Florida Pulmonary Group - Altamonte Springs
- Meris Clinical Research-Brandon-69466 - Brandon
- St. Francis Medical Institute - Clearwater
- North Florida/South Georgia Veterans Health System - Gainesville
- University of Florida College of Medicine - Jacksonville
- Mayo Clinic - Florida - Jacksonville
- University of Miami - Miami
- Essence MD Research - Naples
California
- Newport Native MD, Inc - Newport Beach
- Paradigm Clinical Research - Redding - Redding
- University of California Davis - Sacramento
- University of California San Francisco - San Francisco
- Ventura County Medical Center - Ventura
Arizona
- Dignity Health, St. Joseph's Hospital and Medical Center - Phoenix
- University of Arizona - Tucson
Alabama
- University of Alabama at Birmingham - Birmingham
Alaska
- Providence Medical Group Alaska - Anchorage
Colorado
- National Jewish Health - Denver
Connecticut
- Yale University School of Medicine - North Haven
District of Columbia
- Georgetown University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,755 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2028-10-12 |
| Phase | Phase 3 |
What NCT06872892 shows while recruiting
NCT06872892 is an interventional study that assigns participants to a tested intervention. Its 1,755 participants enrollment target places it among the larger protocols in the corpus, above the 253-participant average among 13 other Bronchiectasis trials with a reported enrollment target (594% higher).
The record links to 1 condition, with Bronchiectasis appearing as the primary indexed condition, and to 2 interventions - of which BI 1291583 is the first listed.
NCT06872892 names 20 study sites across 8 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06872892 about?
NCT06872892 is a clinical study titled "The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis". This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronc...
What is the current status of trial NCT06872892?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,755 participants. The study started on 2025-06-09. Estimated completion is 2028-10-12.
What conditions does trial NCT06872892 study?
This clinical trial studies the following conditions: Bronchiectasis.
What interventions are being tested in trial NCT06872892?
The interventions under investigation include: BI 1291583 (DRUG), Placebo matching BI 1291583 (DRUG).
Who is sponsoring clinical trial NCT06872892?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06872892 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchiectasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06872892's enrollment target sits among peer trials
1,755 1st of 13 higher than 13 of 13 other Bronchiectasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bronchiectasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation Of The Lung Microbiome In NTM Bronchiectasis
RECRUITING
-
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
RECRUITING · NA
-
Itraconazole Therapy In Bronchiectasis With Airway Mold
RECRUITING · Phase 4
-
OLE Therapy With BE Patients in Home Care Study
RECRUITING · NA
-
Natural History of Bronchiectasis
RECRUITING
-
Acoustic Waveform Respiratory Evaluation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07062172 · 1,753 participants · NA
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
- NCT06954337 · 1,750 participants · NA
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
- NCT07183527 · 1,750 participants · NA
Hybrid Type I Effectiveness-implementation Cluster Randomized Controlled Trial of CARES
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI